{'fraction_non_alphanumeric': 0.04459203036053131, 'fraction_numerical': 0.061669829222011384, 'mean_word_length': 4.328282828282828, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Studies on the anticancer effect of HH07A, a derivative of hainanensine].

The effect of HH07A on the growth of tumor cells in vitro was investigated using the techniques of cell growth curve determination and soft-agar colony-forming assay. The result showed that HH07A inhibited the growth of L1210 cells and HL-60 cells at a concentration of 1.5 micrograms.ml-1 and 4.0 micrograms.ml-1, respectively. Among the cells tested, L1210 cells were shown to be the most sensitive, followed by KB cells and HL-60 cells (with IC50 of 2.29, 4.13 and 4.36 micrograms.ml-1, respectively). Normal mouse granulocyte-macrophage progenitor cells (GM-CFC) were less sensitive to the drug (with IC50 of 11.15 micrograms.ml-1) as compared with the tumor cells. As they were exposed to HH07A 3.5 micrograms.ml-1 for 5 days, HL-60 cells did not show NBT reductive ability. Intraperitoneal injection of HH07A exerted inhibitory effect on the ascitic tumors of L1210 and S180 in mice. Oral or ip administration of HH07A also showed some effect on S180 solid tumors in mice.